News

In an analysis of the IRIS database, investigators assessed almost 1,200 eyes that had been treated with faricimab.

KIO-104 is a therapeutic candidate shown to significantly reduce retinal scar formation.

Members of the Ophthalmology Times Europe, Ophthalmology Times and Modern Retina editorial advisory boards are present and presenting at the 2025 ARVO meeting

Wendy Lee, MD, MS, shares how she integrates aesthetic and functional care in oculoplastics.

At the ARVO 2025 Annual Meeting in Salt Lake City, Utah, Nimesh Patel, MD, presented on the LUCIA and LUGANO phase 3 pivotal trials for EYP-1901 against aflibercept for the treatment of wet macular degeneration.

At the ARVO 2025 meeting in Salt Lake City, Utah, Cameron Cummings presented a poster on how retinal microvascular imaging metrics may show sex-specific biomarkers for Parkinson's disease.

Roshan Kenia presented a poster on how AI-CNet3D enhances glaucoma classification using cross-attention networks while improving interpretability and performance in OCT scan analysis.

Verana Health’s newly launched Qdata Cataract offers a comprehensive dataset to improve outcomes, reduce complications and enhance IOL technology.

In the weeks to come, the European Commission will issue a decision on the first severe thyroid eye disease treatment.

Carl Zeiss Meditec plans to launch the ZEISS RDP in select countries throughout 2025

A machine learning model using treated astigmatism and other nuanced inputs can significantly improve the accuracy and personalization of arcuate keratotomy planning

The Virtual Eye Simulation Analyzer is an AI-driven digital twin of the human eye designed to model aging and personalize presbyopia treatment across the lifecycle.

New research links genetic risk for schizophrenia to retinal thinning, suggesting early indicators of the disorder may be found in retinal morphology.

The research team from the University of Cincinnati surveyed 42 patients 50 years of age and older at Hoxworth Eye Clinic

ZEISS Research Data Platform is a cloud-based, AI-driven solution designed to transform ophthalmic research workflows.

The OcuMet Beacon is a proprietary, noninvasive tool for assessing retinal health. The company said it will be available on the US market for use in clinics and health care institutions.

Explore the challenges and strategies of private practice management, focusing on financial sustainability and patient care in today's healthcare landscape.

The clearance expands its existing label from patients aged 4 to 7 years to patients aged 4 to under 13 years.

The OcuMet Beacon is a proprietary, noninvasive tool for assessing retinal health. The company said it will be available on the US market for use in clinics and healthcare institutions.

Retina World Congress 2025 unites global retina experts in Fort Lauderdale to explore cutting-edge research, surgical techniques, and patient care advancements.

4D-150 is a potential backbone therapy that is designed to provide multiyear sustained delivery of anti-VEGF (aflibercept and anti–VEGF-C) to be targeted to the retina with a single, well-tolerated intravitreal injection.

Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor.

Shehzad Batliwala, DO, known to his patients as Dr. Shehz, appeared on the ASCRS Foundation Symposium, where he discussed performing refractive surgery in low-resource, high-risk areas.

LuxIA is designed to screen adult diabetic patients for more-than-mild diabetic retinopathy.